There are 594 resources available
132TiP - Phase Ib open-label study of trastuzumab deruxtecan (T-DXd) + rilvegostomig ± carboplatin as first-line (1L) treatment (Tx) for metastatic HER2-overexpressing (HER2-OE) non-small cell lung cancer (NSCLC): DESTINY-Lung03 (DL-03) part 4
Presenter: David Planchard
Session: Poster Display session
133TiP - A randomized phase III study of ivonescimab versus pembrolizumab as first-line treatment of metastatic non-small cell lung cancer as first-line treatment of metastatic non-small cell lung cancer with high tumor PD-L1 expression: HARMONi-7
Presenter: Antonio Passaro
Session: Poster Display session
Resources:
Abstract
134TiP - Evaluation of an additional cohort of patients with non-small cell lung cancer (NSCLC) in the phase I/II duravelo-1 study of zelenectide pevedotin (BT8009), a bicycle toxin conjugate
Presenter: Capucine Baldini
Session: Poster Display session
138P - Outcomes by treatment (tx) cycles (cyc) with perioperative nivolumab (NIVO) in patients (pts) with resectable NSCLC from CheckMate 77 T study
Presenter: Denis Moro-Sibilot
Session: Poster Display session
139P - Global qualitative assessment of factors affecting multidisciplinary team (MDT) care in early-stage NSCLC
Presenter: Severin Schmid
Session: Poster Display session
140P - Neoadjuvant lazertinib therapy guided by EGFR mutation detection in BALF for resectable lung cancer: Prospective real-world phase II study
Presenter: In Ae Kim
Session: Poster Display session
142P - Identification of the lymph node metastasis atlas and optimal lymph node dissection strategy in patients with resectable lung invasive mucinous adenocarcinoma: A real-world multicentre study
Presenter: Jie He
Session: Poster Display session
Resources:
Abstract
143P - Microwave ablation versus lobectomy for ground-glass opacity nodules in the hilar region: A multicenter prospective real-world study on efficacy and safety
Presenter: Wangrui Liu
Session: Poster Display session
144P - Perioperative immunotherapy treatment in resectable non-small cell lung cancer with KRAS mutation: A real-world study (Peri-R-01)
Presenter: Hua Zhong
Session: Poster Display session
145P - Efficacy and safety of aumolertinib as adjuvant therapy in resectable stage I A NSCLC with high-risk factors and EGFRsensitizing mutations (APPOINT)
Presenter: Baohui Han
Session: Poster Display session